InsidersTradesSigma
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Explore the full record of transactions filed by Marks Gilbert Lynn. Director active across 1 company, notably AN2 Therapeutics, Inc.. Cumulatively, 7 disclosures have been published. History available since 19 December 2024. The latest transaction was disclosed on 10 July 2026 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
7 of 7 declarations
Marks Gilbert Lynn is a declarant linked to AN2 Therapeutics, Inc., where he is Director. He has 4 filings in total, and the 4 sampled filings run from 2024-12-23 to 2026-04-10, with transaction nature listed as Attribution and buy and sell amounts of EUR 0 in this recent sample.